This book critically evaluates the causal link between cell division machinery and disease. Further, it identifies key open questions in the field and the means for exploring them. Throughout the various chapters, internationally known contributors present the evidence for and against a causal link between key elements of the cell division machinery and diseases such as cancer, neuropathologies, aging, and infertility. A more clinically oriented chapter further discusses the current and future applications of anti-mitotic drugs in these diseases. Cell Division Machinery and Disease is essential reading for graduate or advanced graduate students, researchers or scientists working on cell division as well as clinicians interested in the molecular mechanisms of the discussed diseases.

This volume began with an invitation from the publishers to edit a volume of EXS on Cancer. This invitation undoubtedly derived from my articles in Cellular and Molecular Life Sciences in 2002 and 2003 on the relationships between the morphology, aetiology and pathogenesis of tumours, especially in relation to genetic instability. After many years of teaching the theories of c- cer in undergraduate medical school courses, it seemed to me that the variably chaotic histopathologic features of tumours parallel in some way, the variably unstable genomes of tumour cells, which were being discovered in the 1990s. Thus the title of the volume has come to include morphology, carcinogenesis and genetic instability. The invitation came while I was working with Herrn Dr. med. Hubertus Jersmann (MD Dusseldorf, PhD, now Senior Lecturer in Medicine of the University of Adelaide) and Professor Brian Coghlan (Emeritus Professor of German, the University of Adelaide), on the work of the nineteenth century cancer pathologists, especially David Paul von Hansemann (1858-1920). With the delivery of the manuscripts from the authors of the chapters, it became obvious that a background chapter for the volume could include some of the material which we had "uncovered" together. Because of this, chapter 1 is authored by the three of us, and the "new" material figures prominently.

In the past five years, a surprising and intense resurgence in interest in vitamins and other micronutrients and their role in health and dis ease has occurred. The recognition has emerged that vitamins not only are essential for life .in that severe nutritional deficiencies occur in their absence, but that these compounds may also serve as natural inhibitors of cancer. Synthetic alterations of the basic vitamin A mole cule have also resulted in the production of compounds that are more potent as anticancer agents than the natural substance and may have substantial therapeutic activity as well. Whether other vita mins can be changed or altered to produce a better anticancer effect than the native compound has been little explored to date, but should be a fruitful pursuit for future study. In our concluding remarks to the First International Conference in 1982, we speculated that rapid advances in our understanding of vi tamins would occur in the next few years and that large-scale inter vention trials of vitamins as preventive agents in defined human pop ulations would be started. This anticipated generation of data on vitamins and their interactions has proceeded rapidly and the impor tance of interactions between vitamins and other micronutrients in the prevention setting has become better appreciated. Currently, more than 25 intervention trials with a variety of target populations using vitamins and other micronutrients have been started, but it re mains too early for meaningful analysis of the results to date."

This multidisciplinary reference explores the concepts and realities of quality of life among cancer survivors in its physical, psychological, cognitive, social, and familial dimensions. Informed by a broad range of fields including genetics, psychiatry, nursing, dentistry, rehabilitation, and ethics, it addresses daily challenges of living for this population, from self-care to cultural concerns and from social interactions to experiences with providers. Family issues of pediatric, young adult, and elder survivors, caregiving parents, and siblings are a major area of concern. And contributors describe interventions for survivors as individuals, in family content, and as part of integrated care across primary and specialty settings. Included among the topics: Play, leisure activities, and cognitive health among older cancer survivors. Genetic mutations in cancer susceptibility genes: a family history of cancer. Cancer patients in a pediatric intensive care unit: a single center experience. The impact of childhood cancer on the quality of life among healthy siblings. When cancer returns: family caregivers and the hospice team. Experiencing cancer services: a story of survival and dissatisfaction. A significant addition to the cancer survivorship literature, Quality of Life Among Cancer Survivors is a practice-building resource for oncology and allied health professionals, health psychologists, and social workers, as well as researchers in these fields.

Lymphangiogenesis and Cancer Metastasis introduces the new field of lymphatic vessel growth and development, and its relationship to the metastatic spread of cancer cells.

The book covers all aspects of this new field from the fundamental role that protein growth factors and their receptors play in lymphangiogenesis to the potential application of these advances to cancer diagnosis and treatment. Other clinical aspects explored include the mechanisms and importance of lymph node metastasis, the role of the lymphatics in lymphangioleiomyomatosis and Kaposi s sarcoma, and approaches for imaging lymphatics in cancer.

The book also covers the innovative approaches taken by researchers to explore new roles for lymphatic vessel biology in the context of cancer. The information presented in this volume, which describes the revolutionary concepts of tumor lymphangiogenesis, will be of interest to all students, scientists and oncologists who are seeking to understand the complexities of tumor metastasis.

Key Features:

• Presents fundamental concepts of tumor lymphangiogenesis and the molecules which control this process
• Provides a comprehensive summary of current research in this ground breaking area
• Provides a book which links progress in basic tumor and developmental biology with current and future oncology practise
• Is an essential text for molecular biologists, cell biologists and oncologists seeking to understand the implications of this rapidly developing area.

The contents of this book will be organized into three sections. The first section defines the scope, impact and behaviour of cancer regimen-related toxicities and frames the issue of balancing treatment success and physiological cost. In the second segment of the book, the most current thinking around the pathobiology of specific, common, and representative toxicities is presented by leading researchers and translational scientists. The final portion of the book discusses the common biological relationships between toxicities, bioinformatical approaches to analysing key and common pathways, and strategies for the development of effective interventions.

Liver Cancer, the inaugural volume in the M.D. Anderson Solid Tumor Oncology series, provides the general surgeon, surgical oncologist, and medical oncologist with the most up-to-date and current standard of multimodality care for hepatobiliary cancer. Surgical approaches, chemotherapy, immunotherapy, gene therapy, and radiotherapy are all presented, giving the practitioner a much needed, comprehensive perspective on all aspects of patient care. The MD Anderson Solid Tumor Oncology series features cutting-edge, indepth information of vital interest to all practitioners in today's captitated financial milieu. Providers must understand how their component of care interdigitates with the varied medical and surgical teams and apply multimodality approaches to their practice environments.

This book presents the state of the art of biostatistical methods and their applications in clinical oncology. Many methodologies established today in biostatistics have been brought about through its applications to the design and analysis of oncology clinical studies. This field of oncology, now in the midst of evolution owing to rapid advances in biotechnologies and cancer genomics, is becoming one of the most promising disease fields in the shift toward personalized medicine. Modern developments of diagnosis and therapeutics of cancer have also been continuously fueled by recent progress in establishing the infrastructure for conducting more complex, large-scale clinical trials and observational studies. The field of cancer clinical studies therefore will continue to provide many new statistical challenges that warrant further progress in the methodology and practice of biostatistics. This book provides a systematic coverage of various stages of cancer clinical studies. Topics from modern cancer clinical trials include phase I clinical trials for combination therapies, exploratory phase II trials with multiple endpoints/treatments, and confirmative biomarker-based phase III trials with interim monitoring and adaptation. It also covers important areas of cancer screening, prognostic analysis, and the analysis of large-scale molecular data in the era of big data.

The European Organization for Cooperation in Cancer Prevention Studies (ECP) was established in 1981 to promote collaboration between scientists working in the various European countries on cancer causation and prevention. In order to achieve this aim, various working group- to deal with specific cancers or aspects of cancer aetiology, and to explore the opportunities for advances on a cooperative European basis - were established. It was also decided to hold annual symposia to draw general attention to fields in which there seemed to be many opportunities for progress in matters of prevention. These symposia have been devoted to themes of high priority to cancer prevention: "Tobacco and Cancer" (1983), "Hormones and Sexual Factors in Human Cancer Aetiology" (1984), "Diet and Human Carcinogenesis" (1985), "Concepts and Theories in Carcinogenesis" (1986)," Preventive Strategies for Cancer related to Immune Deficiencies" (1987), "Gastric Carcinogenesis" (1988), and "Breast, Ovarian and Endometrial Cancer: Aetiological and Epidemiological Relationships" (1989). This volume contains the proceedings of the 1990 ECP symposium held in Heidelberg, FRG, at the Deutsches Krebsforschungszentrum (DKFZ), on April 2-3 on "Causation and Prevention of Human Cancer." We are indebted to the speakers for their contribution during the symposium and for their prompt submission of manuscripts. We are grateful to the sponsors, SmithKline Diagnostics and Rohm Pharma. Our special thanks go to Dr M.C. stanei-Gueur for preparing and typing the camera forms of all manuscripts.

This second edition has been updated in a user-friendly layout that makes its comprehensive information extremely accessible. The handbook, written for all physicians who treat cancer patients, provides a survey of current therapeutic concepts of solid tumors and hematologic malignancies in internal oncology. Each individual chapter of this shortened new edition is structured in the same way and features a brief outline or tabular summary of the main aspects of epidemiology, pathology, staging, and diagnosis. The main focus is on the therapeutic strategy, i.e., an interdisciplinary approach to systemic drug therapy. Surgical and radiological concepts of treatment are also covered, as are supportive care, pain relief methods and ethical problems. This title is a must for clinicians and practitioners as well as interns, residents and postgraduate students.

Advances in genetics are transforming estimates of an individual 's risk of developing cancer and approaches to prevention and management of cancer in those who may have increased susceptibility. Identifying and caring for patients with hereditary cancer syndromes and their family members present a complex clinical, scientific and social challenge. This textbook, by leading experts at Massachusetts General Hospital Cancer Center, highlights the current understanding of the genetics of hereditary cancers of the breast, ovary, colorectum, stomach, pancreas, kidney, skin, and endocrine organs. Practical guidelines for the use of genetic testing, cancer screening and surveillance, prophylactic surgery, and promising targeted therapeutic agents are discussed.

In addition, ongoing research involving genome-wide screens to identify novel modest risk-associated genetic loci are explored, along with new approaches to the application of genetic markers in guiding therapeutic options.

A cutting-edge review of the important issues underlying the therapeutic use of nucleic acid-mediated gene silencing. Topics range from basic methodology and delivery to targeting and clinical targets. The authors thoroughly explain the latest developments in RNA biology, as well as the underpinnings of RNA interference, oligodeoxynucleotide delivery into cells, and strategies for targeting these molecules to accessible regions within the mRNA. They also provide some examples of how these new therapeutic compounds are being used clinically.

How hype, money, and bias can mislead the public into thinking that many worthless or unproven treatments are effective. Each week, people read about new and exciting cancer drugs. Some of these drugs are truly transformative, offering major improvements in how long patients live or how they feel-but what is often missing from the popular narrative is that, far too often, these new drugs have marginal or minimal benefits. Some are even harmful. In Malignant, hematologist-oncologist Dr. Vinayak K. Prasad writes about the many sobering examples of how patients are too often failed by cancer policy and by how oncology is practiced. Throughout this work, Prasad illuminates deceptive practices which * promote novel cancer therapies long before credible data are available to support such treatment; and * exaggerate the potential benefits of new therapies, many of which cost thousands and in some cases hundreds of thousands of dollars. Prasad then critiques the financial conflicts of interest that pervade the oncology field, the pharmaceutical industry, and the US Food and Drug administration. This is a book about how the actions of human beings-our policies, our standards of evidence, and our drug regulation-incentivize the pursuit of marginal or unproven therapies at lofty and unsustainable prices. Prasad takes us through how cancer trials are conducted, how drugs come to market, and how pricing decisions are made, asking how we can ensure that more cancer drugs deliver both greater benefit and a lower price. Ultimately, Prasad says, * more cancer clinical trials should measure outcomes that actually matter to people with cancer; * patients on those trials should look more like actual global citizens; * we need drug regulators to raise, not perpetually lower, the bar for approval; and * we need unbiased patient advocates and experts. This well-written, opinionated, and engaging book explains what we can do differently to make serious and sustained progress against cancer-and how we can avoid repeating the policy and practice mistakes of the past.

In recent years, there have been major advances in the treatment of patients with gynecologic malignancies. Perhaps the biggest advances have been in the area of ovarian cancer. Gynecologic Oncology focuses primarily upon this malignancy. This volume discusses cytoreductive surgery; screening for ovarian cancer; chemotherapy; new chemotherapeutic drugs; the controversy regarding the role of high-dose chemotherapy in gynecologic cancers; the hereditary basis for gynecologic malignancies; molecular genetics; molecular biology and new biologic therapies. Other topics covered are the treatment of all stages of cervical cancer, including radiotherapy. In addition, a chapter on advances in the pathology of gynecologic cancers is included. The advances made in the treatment of gynecologic malignancies are due, in part, to the clinical studies performed by many of the contributors to this volume. Clinical advances have been the result of multidisciplinary approaches which involve molecular biologists, pathologists, radiation therapists, surgeons and chemotherapists. Future advances will continue to rely upon collaborative interaction among these different disciplines.

Effective control of breast cancer depends on three types of research accomplishment -- understanding the disease's origins and progression: successfully applying this knowledge to methods of detection, diagnosis and treatment: and finding ways to make these advances truly available to the public as effectively as possible. The significant progress that is occurring across this entire spectrum of pioneering investigation is reflected in these proceedings of the 1987 biennial conference of the International Association for Breast Cancer Research. The first section of the book focuses on oncogenes and chemical effectors that may play key roles in early cell transformation leading to breast cancer. Research discussed includes identification of specific oncogenes which appear to be involved in the disease, study of their activation and expression, examination of the biological effects of various growth factors isolated from breast cancer cell lines, and investigation of the molecular mechanisms by which estrogens promote and stimulate growth of breast cancers. The second group of chapters deals with several other complex factors and phenomena which may influence tumor formation in the breast, for example, expression of abnormalities by fibroblasts, disruption of epithelial-mesenchymal interactions, and loss of ability nili to synthesize normal basal lamina resulting in alterations in the extracellular matrix. Clarification of the processes of normal mammary gland development and differentiation is central to much of this work.

The most comprehensive guide available on hereditary cancers, from understanding risk, prevention, and genetic counseling and testing to treatment, quality of life, and more. Up to 10 percent of cancers are caused by inherited mutations in specific genes. Finding out that you or your loved ones may be at increased risk of developing cancer because of a genetic mutation raises a lot of questions: Is cancer inevitable? Is there anything I should do differently in my life? Will my children also be at higher risk of cancer? Should I have preemptive treatments or surgery? This comprehensive guide provides answers to these questions and more. Written by three passionate patient advocates, this book is a compilation of the trusted information and support provided for more than two decades by Facing Our Risk of Cancer Empowered (FORCE), the de facto voice of the hereditary cancer community. Combining the latest scientific research with national guidelines, expert advice, and compelling patient stories, the book offers previvors (those who have a mutation but have never been diagnosed), survivors, and their families the guidance they need to face the unique physical and emotional challenges of living in a high-risk body. An ideal resource for genetic counselors, physicians, nurses, advocates, and others who support and care for the hereditary cancer community, Living with Hereditary Cancer Risk also provides coverage of * signs of inherited cancer risk in a family; * the value of genetic counseling and testing; * mutations in BRCA, Lynch Syndrome, and other genes that elevate cancer risk; * risk-reducing strategies; * traditional treatments and newer personalized approaches, including immunotherapies and PARP inhibitors; * nationally recommended guidelines for prevention, early detection, and treatment; * insurance coverage and discrimination protections; and * coping with sexual health, fertility, menopause, and other quality of life issues.

Since the discovery of microRNAs (miRNAs) some twenty years ago by Victor Ambros, David Baulcombe and Gary Ruvkun, these three scientists worked to uncover the mystery of miRNA, the small segments of nucleotides that silence genes. While studying the development of the nematode worm, Ambros and Ruvkun discovered miRNA in animals, while Baulcombe discovered it in plants. Since their discovery, it took more than two decade to fully appreciate the value of miRNA in human health and diseases. Emerging evidence suggest that the activation of oncogenes and/or the inactivation of tumor suppressor genes contribute to the development and progression of tumors. The regulation of genes is by far controlled by many transcription factors which are often deregulated during the development and progression of cancer. In addition, emerging evidence clearly suggests that the deregulation of miRNAs or small non-coding RNAs could also regulate the expression of genes, and likewise, miRNA genes are also regulated by transcription factors. The most attractive feature of miRNAs is that one miRNA can regulate many target genes (mRNAs), and thus miRNA targeted therapy is highly promising because multiple genes could be regulated by targeting a single miRNA, which becomes very important for the killing of highly heterogeneous populations of cancer cells within a tumor mass. Therefore, miRNA targeted therapy is an attractive attribute of miRNA research, which is covered through eighteen chapters complied in this book "MicroRNA targeted Cancer therapy," and it is hoped that the field of miRNA research will be appreciated through critical reading of these chapters on the cutting-edge research on miRNAs.

During the past four decades knowledge about biological effects of ionizing radiations on mammalian cells, normal tissues and tumours has increased enormously and has enabled radiotherapists to obtain a better insight into the advantages and disadvantages of cancer treatments with modified regimens of irradiations and combinations with chemotherapeutic agents. Even for the older scientists and clinicians who have wit nessed all these developments and have contributed to the vast amount of information, it is difficult to integrate this knowledge and to apply it in their daily work. For younger workers it is often difficult to select the important main concepts and results from the overwhelming number of publications. It is evident that a book which provides an integrated view of basic and applied radiation oncology can be of great value to students, scientists and, most importantly, to clinicians who can devote only part of their time to the task of understanding the radiobiological background of their application of radiation in cancer treatment. This book "Radiation Oncology" is written by a radiotherapist who has for a long time participated in the integration of basic knowledge and clinical experience. He has selected radiobiological information which is considered important to radiotherapy and in the description and interpretation of normal tissue tolerance and tumour eradication probability, he illustrates how basic knowledge can be applied clinically."

It has been generally accepted that angiogenesis is involved in the pathogenesis of hematological malignancies, like acute and chronic leukemia, lymphoma, myelodysplastic syndromes, myeloproliferative neoplasms and multiple myeloma. The extent of angiogenesis in the bone marrow has been correlated with disease burden, prognosis and treatment outcome. Reciprocal positive and negative interactions between tumor cells and bone marrow stromal cells, namely hematopoietic stem cells, fibroblasts, osteoblasts/osteoclasts, endothelial cells, endothelial progenitor cells, T cells, macrophages and mast cells, mediated by an array of cytokines, receptors and adhesion molecules, modulate the angiogenic response in hematological tumors. More recently, it has been emphasized the pro-angiogenic role of the so called "vascular niche," indicating a site rich in blood vessels where endothelial cells and mural cells such as pericytes and smooth muscle cells create a microenvironment that affects the behavior of several stem and progenitor cells, in hematological malignancies.

Statistical methods for clinical trials have been an area of active research in Biostatistics since the first modern clinical trials were mounted in 1946 by the British Medical Research Council in whooping cough and tuberculosis. Often, the participants in clinical trials suffer from potentially fatal chronic diseases, and it is especially important that these experiments in medical research use designs that are efficient, can be understood by physicians, policy makers and patients, respond quickly new ideas in medicine and statistics, and, perhaps above all, show respect for the complex and important ethical issues that arise in these settings. This book explores some recent thinking in designs for clinical trials, including alternative designs for phase I studies, interim monitoring for futility, adaptive designs based on accumulating outcome data, and designs of new, targeted therapies. The book is intended for both the statistical practitioner, who may be too busy to stay abreast of the literature on statistical methods, as well as statisticians conducting research in clinical trials.

Oncofertility integrates the two previously distinct fields of cancer treatment and fertility research and aims to explore and expand the reproductive future of cancer survivors. In order to achieve the goal of fertility preservation, the Oncofertility community must focus on communication and the way data is provided and received. Concomitant with the rapidly changing technology of Oncofertility, there have been radical shifts and advances in the way health educators and clinicians can produce and share information.As success rates of reproductive techniques such as egg freezing and banking continue to rise, providing increasing opportunities for young cancer patients to preserve their fertility prior to the onset of cancer treatments, communication among professionals in oncology, reproductive medicine, and psychosocial work, among others, becomes crucial, and clinical demand for Oncofertility information is expected to rise considerably.

"Oncofertility Communication" describes and addresses the myriad channels through which the multiple audiences involved in Oncofertility can be served with appropriate and accurate information about cancer-related fertility issues. The text answers frequently asked questions and provides invaluable insights to scientific and health care professionals about communication among the diverse Oncofertility audiences. It incorporates timely discussions about traditional and emerging electronic communication tools and discusses the impact of health care policy changes on the Oncofertility field. "

Metastatic dissemination of cancer is a main cause of cancer related deaths, therefore biological mechanisms implicated in metastatic process presents an essential object of cancer research. This research requires creation and utilization of adequate laboratory models. The book describes main approaches to model processes of metastatic cancer dissemination and metastases development. The book is structured in according with various metastatic pathways reflecting molecular specificity of metastatic process as well as anatomical specificity of aria of dissemination. Each chapter is introduced by short discussion of clinical aspects of certain metastatic pathway. Especial attention is paid for methods of visualization, quantification and analysis of the modeled metastases. Additional chapter is devoted to methods of mathematic modeling of tumor spread. The data presented in the book may be helpful for cancer researchers and oncologists.

Protein kinase C (PKC), a family of serine-threonine kinases, rocketed to the forefront of the cancer research field in the early 1980's with its identification as an effector of phorbol esters, natural products with tumor promoting activity. Phorbol esters had long been of interest to the cancer research field due to early studies in the mouse skin carcinogenesis model, which showed that prolonged topical application of phorbol esters promoted the formation of skin tumors on mice previously treated with mutagenic agents. Research in the last years has established key roles for PKC isozymes in the control of cell proliferation, migration, adhesion, and malignant transformation. In addition, there is a large body of evidence linking PKC to invasion and cancer cell metastasis. Moreover, it is now well established that the expression of PKC isozymes is altered in various types of cancers. More importantly, small molecule inhibitors have been developed with significant anti-cancer activity. The relevance of PKC isozymes in cancer signaling is therefore remarkable. This book will have 4 sections. There will be 23 chapters. Each section will have a brief introduction by an expert in the field (~ 1-2 pages).

Oxidation-reduction (i.e. redox) processes at the plasma membrane of any cell have been attracting more and more attention, both in basic and in applied research, since the first workshop dealing with the plasma membrane oxidoreductases was organized in Cordoba, Spain, in 1988. This evolution is evident considering the numerous cell functions performed by plasma membrane redox systems not only in healthy cells but also in cells that escaped from the normal metabolic control (e.g. cancer cells) and cells under attack by pathogens. Plasma membrane redox processes have now been demonstrated to play an essential role in growth control and defense mechanisms of these cells. The great importance of the plasma membrane redox systems originates in the fact that they are located in the membrane which is essentially the site of communication between the living cell and its environment. We may say that the plasma membrane can be considered as the "sensory part" of the cell. No chemical substance can enter the cell interior without interaction with the plasma membrane.